In agreement with more recent findings in the general NSCLC population and in the subset of EGFRM+ LACs [12,46], our EGFRM+ NSCLC cohort displayed an overall frequency of MET copy number gain of 22% and high concordance between MET-amplification and MET-overexpression, though we also observed a few cases with MET-overexpression not associated with gene amplification [51], which is a relatively frequent event in NSCLC [46,133]. The gene discussed is MET; the disease is non-small cell lung carcinoma.